Services
IndustriesStaffing & RecruitingSaaSFintechMartechConstruction TechMarketing AgenciesConsultingHealthTechCybersecurityLegalTechHRTechIT ServicesAccountingLaw FirmsProptechEdTechLogistics TechInsurTechDevToolsData & Analytics
Case Studies Resources About Let's chat
Medical consumables and disposables

Selling medical consumables in India:
built on the reorder, not the sale

Capital equipment is a committee decision made once. A consumable is a reorder decision made every few weeks, through a distributor's stocking depth and a rate contract most manufacturers never read closely enough. Get the volume model and the margin rules wrong, and the first sale is also the last one.

For manufacturers of medical consumables and disposables · We run the commercial track only, and we say so on the page

How is selling medical consumables into India different from capital equipment or diagnostics?

The sale that matters is the second one, not the first. A consumable or disposable, sutures, syringes, catheters, dressings, surgical drapes, gloves, enters a hospital or chain through central stores and materials management, not a clinical committee, and it is reordered on a cycle, against a rate contract or an empanelment list, rather than bought once. Getting onto that list is a separate, often tender-driven campaign; staying on it depends on fill rate and consistent supply more than on the product itself. The Legal Metrology labelling history is different too, and the margin on the product sits under more active regulatory attention than either capital equipment or diagnostics: NPPA has already capped trade margins once on a defined list of devices, and a 2026 state survey that found hospital consumable markups running into four figures is, as of this page, still under review at the national level.

Montazzo runs the commercial side of this: finding the distributors who already hold rate contracts, reaching the hospitals and chains who reorder, and running the sales motion. We hold no import or wholesale licence, are not anyone's India Authorized Agent, and do not file with CDSCO or bid on your behalf in any tender. If a firm offers to do both in one contract, ask whose name is on the tender submission.

Why is a consumables sale a reorder decision, not a one-time purchase?

Because the product that gets bought once is the capital device. A consumable gets bought again every few weeks, for as long as it stays on an approved list.

Commercial modelHow it is pricedWhat actually decides the dealWhere you see it
Direct stocking agreement
A distributor carries your line and supplies hospitals and clinics directly from stock.
A standing price list, usually revisited annually, with the distributor's margin built in.Fill rate and consistency of supply. A distributor who is out of stock twice loses the next reorder to whichever competing line is in stock.Private hospitals, nursing homes, clinic chains and most retail-adjacent institutional buying.
Public tender / rate contract
A government hospital, state medical corporation or PSU buyer runs a tender and signs a rate contract with the winning bidder.
The lowest price among bidders who clear the technical qualification, locked for the contract term.Technical compliance, documentation, and whether your distributor is the one actually named on the contract.Government hospitals, medical colleges and PSU buyers such as HLL Lifecare and state medical services corporations, increasingly routed through GeM.
Hospital group empanelment
A private hospital chain adds your line to its approved-vendor and approved-product list at the group level.
A negotiated schedule set once at group level, then drawn down by individual hospitals in the chain.Getting onto the list in the first place, which is a procurement campaign run once a year or less, not a sales call.Large private hospital chains and diagnostic groups with centralised procurement.

All three models share one feature a capital equipment sale does not: the contract or the agreement outlives any single order. A rate contract commonly runs one to two years before it is retendered, and empanelment is reviewed on a similar cycle. The commercial work that matters most is not winning the first order, it is staying eligible to receive the next one.

Does the Legal Metrology MRP rule still apply to a consumable pack?

It depends on when you check, and the answer has changed twice. From January 2018, medical devices, including the 22 categories notified as drugs under the Drugs and Cosmetics Act, were brought under the Legal Metrology (Packaged Commodities) Rules and required to carry a declared maximum retail price on the pack, along with a mandatory country of origin declaration for imported devices. That rule applied to disposable and consumable packs the same way it applied to capital equipment labelling, because Legal Metrology governs any pre-packaged commodity, not just devices with a high unit price.

The Legal Metrology (Packaged Commodities) Amendment Rules, 2025 moved medical devices out of that regime entirely. Labelling, including the declarations that previously sat under Legal Metrology, is now governed solely by the Medical Devices Rules, 2017. The practical declarations, MRP, manufacturing details, net quantity, have not disappeared, they now live under a different code with its own font size and display requirements. For a consumable specifically, where the pack is often smaller and the print area tighter than on a capital device box, that distinction is worth getting right before you commission packaging artwork.

What this means for packaging.

Do not assume your capital equipment packaging consultant's sign-off covers your consumable line, or the reverse. Check the current labelling requirement for your specific category directly against the Medical Devices Rules, 2017 before finalising pack artwork, rather than carrying over a declaration format from a different product class.

Is a consumables distributor's margin about to be capped?

This is the live question on this category, and nobody, including Montazzo, can tell you how it ends. In 2021, the National Pharmaceutical Pricing Authority used its Paragraph 19 powers under the Drugs (Prices Control) Order to cap trade margins at 70% on six COVID-era devices, oxygen concentrators, pulse oximeters, glucometers, BP monitors, nebulisers and digital thermometers, after finding that trade margins on those products ranged from roughly 3% to 709% between what the distributor paid and what the patient was billed.

That precedent is why a 2026 finding matters. A Maharashtra FDA survey found markups on common hospital consumables running as high as roughly 2,800% between distributor cost and patient billing, and the Department of Pharmaceuticals has directed NPPA to review the finding and report back. As of this page, that review has not produced a published order extending a margin cap to the broader consumables category, and we are not going to guess at what it will say. State drug regulators separately have documented comparable markups on hospital consumables for years without a resulting national cap, so a review starting is not the same as a cap landing. Treat this as live regulatory risk to price into any distribution agreement you sign now, not as a settled fact either way.

What this means for your distribution agreement.

If your distributor's margin on your line is wide enough that a future cap would make the relationship unprofitable for them, that is useful to know before you sign, not after. Ask what margin they are actually working with, and whether the commercial terms you are agreeing to survive a cap being introduced mid-term. The same caution applies to the capital device side of your range: see where margins sit on medical devices for the broader context.

Who actually controls the reorder, and what are they optimising for?

Different people from a capital purchase, and they move faster once you are in, slower to let you in the first time.

  • Central stores or materials management. Owns the reorder itself: consumption-linked ordering, minimum stock levels, and whether your distributor's fill rate has been reliable enough to stay the default supplier.
  • CSSD or infection control, for sterile and single-use items. Owns compliance with sterilisation and single-use policy, and can block a product on documentation grounds even when price and supply are both fine.
  • Pharmacy and purchase committee. Owns the formal approval that gets a product onto the hospital's list in the first place, usually an annual or less frequent cycle, and is a committee decision even though the reorder that follows is not.
  • Finance. Owns the budget line and, in the public sector, the rate contract ceiling price; cares about predictable unit cost more than about any single negotiation.
  • The distributor's own stocking depth. Not a hospital role, but the thing that determines whether any of the above ever see a stockout. A distributor who under-stocks is the most common reason a reorder goes to a competing line.

Compare that with a capital device, where a clinical champion has to want the machine before anyone else is asked to agree. A consumable rarely has a clinical champion at all. It has an approved vendor list, and the sale is won or lost at the point that list is built, not at the point any single box is ordered.

How do GeM and public tenders change a consumables sale?

Public hospitals, medical colleges and PSU buyers run consumables procurement on a rate contract cycle rather than a one-off purchase order, and four things about that cycle are worth knowing before you bid.

  • The contract term is usually measured in years, not orders. Published tenders for surgical consumables commonly run two-year rate contracts, renewed or retendered rather than resold.
  • A distributor bidding on your behalf is usually tied to your authorisation. Tender documents typically require a distributor to produce a manufacturer's authorisation letter, and for the Bureau of Pharma PSUs of India, now under HLL Lifecare, a distributor bid is commonly backed by a tri-party agreement naming the manufacturer directly.
  • Bid security is real money, and it is routinely lost on paperwork. Tenders commonly carry an earnest money deposit in the low single digit percentage of bid value and a performance security once awarded, and technical disqualification on documentation, not price, is a common reason a bid fails.
  • Procurement is moving onto GeM. A growing share of public hospital consumables demand runs through the Government e-Marketplace rather than paper tenders, which changes how a listing gets found but not the underlying rate contract logic.

Exact deposit percentages, contract terms and qualification rules vary by buyer and are published in the specific tender, not set by a single national rule, so check the live document for your category rather than budgeting against an example. The GeM authority is GeM.

The shape of the opportunity

70%NPPA's 2021 trade margin cap on six COVID-era devices, imposed after margins on those products were found running from roughly 3% to 709%
~2,800%the markup a 2026 Maharashtra FDA survey found on some hospital consumables, now under review by NPPA with no published cap yet
1 to 2 yrstypical term of a public hospital rate contract for surgical consumables before it is retendered
2018the year medical devices, consumable packs included, first came under mandatory MRP labelling; moved to Medical Devices Rules only labelling in 2025

None of these numbers describe demand, because nobody publishes a clean market size for Indian medical consumables broken out from devices. What they describe is risk and structure: a margin environment under active regulatory attention, a labelling regime that changed twice in under a decade, and a buying cycle built around a multi-year contract rather than a single sale. A distributor or agency pitch that ignores all three is pitching a device sale into a consumables market.

What Montazzo runs

We run the commercial track. We do not touch the regulatory track.

We do: distributor and stockist mapping, outreach into hospital central stores, purchase committees and distributor principals, tracking which rate contracts and empanelment lists are open for renewal, and the sales motion once a regulatory partner is in place.

We do not: act as your India Authorized Agent, hold any import, wholesale or manufacturing licence, file anything with CDSCO, bid on a tender in our own name, or take title to your goods. We do not give regulatory or legal advice, and this page is not any.

Related: the capital equipment version of this split is on selling medical devices in India, the reagent rental model for lab equipment is on selling diagnostic equipment in India, and the demand side across Indian healthcare generally is on our hospital and clinic network. If your distributor is also proposed as your Authorized Agent, read what that combination actually ties you to before you sign. For the wider set of entry routes, start at selling your product in India.

FAQ

Questions medical consumables manufacturers ask us

Not automatically. The same Authorized Agent structure applies whenever your product needs an import or wholesale licence at all, regardless of whether it is a capital device or a consumable. What is different is the sales cycle that follows: a consumable reorders against a rate contract or an approved vendor list, so losing a distributor relationship threatens a recurring revenue stream rather than a single pending order.

The declarations have not gone away, but the rulebook changed in 2025. Medical devices, consumable packs included, were brought under Legal Metrology MRP labelling from January 2018 and moved out of that regime under the 2025 amendment, with labelling now governed solely by the Medical Devices Rules, 2017. Check the current requirement for your specific category directly rather than reusing an older format.

Possibly, and we will not pretend to know the outcome. NPPA capped trade margins on six specific COVID-era devices in 2021, and a 2026 state survey finding very high consumable markups has triggered a national review with no published cap yet. Ask your distributor what margin they are actually working with and build the agreement to survive a cap being introduced mid-term, because the review is live and the direction is not guaranteed.

Usually through an Indian distributor rather than directly. Tenders typically require the bidder to be an Indian entity with a manufacturer's authorisation, and for PSU buyers a distributor bid is commonly backed by a tri-party agreement naming you directly. Check the specific tender's qualification terms before assuming eligibility either way.

In most cases, yes, for the commercial groundwork. Distributor mapping, early conversations with hospital central stores, and tracking which rate contracts or empanelment lists are coming up for renewal can run in parallel with your regulatory process. What we will not do is take orders or imply the product is cleared for sale before it actually is.

A pharmacy or purchase committee makes the formal approval, usually on an annual or less frequent cycle, often with input from CSSD or infection control on sterile and single-use items. Once a product is on the list, the day to day reorder decision sits with central stores or materials management and depends mainly on your distributor's stocking reliability, not on a fresh sales pitch each time.

Tell us which Indian rate contracts or lists you are trying to get onto

A 30-minute call. We tell you whether your category sells through direct distribution, tender or empanelment in India, who actually controls the reorder, and what we would run.

Let's chat